Table 2:

Patients and transplant characteristics in the ‘low’ and ‘high’ risk subgroups

	Good or intermediated cytogenetic risk at diagnosis&<10% blasts			Poor or very poor cytogenetic risk at diagnosis&<10% blasts
	CD34 SELECTED (N=39) MSKCC cohort	Unmodified (N=46) MDACC cohort	P value	CD34 SELECTED (N=19) MSKCC cohort	Unmodified (N=41) MDACC cohort	P value
Median follow-up, month (range)	43.4 (3.8–109.2)	44.9 (12.9–115.6)	-	52.0 (16.2–119.5)	53.3 (14.2–93.9)	-
Age, years (range)	56.9 (21.9–72)	55.5 (25–69)	0.357	59.2 (26.7–69)	58 (32–72)	0.994
Female gender	23 (59.0)	17 (37.0)	0.071	9 (47.4)	13 (31.7)	0.377
MDS-t	3 (7.7)	8 (17.4)	0.316	4 (21.1)	16 (39.0)	0.280
Cytogenetic risk at diagnosis			0.148			0.042
Good	24 (61.5)	36 (78.3)		-	-
Intermediate	15 (38.5)	10 (21.7)		-	-
Poor	-	-		11 (57.9)	11 (26.8)
Very poor	-	-		8 (42.1)	30 (73.2)
Blasts at transplant			0.465			0.016
< 5%	30 (76.9)	31 (67.4)		17 (89.5)	22 (53.7)
5–9%	9 (23.1)	15 (32.6)		2 (10.5)	19 (46.3)
Donor type			0.001			0.008
Match related	15 (38.5)	25 (54.3)		5 (26.3)	21 (51.2)
Match unrelated	14 (35.9)	21 (45.7)		10 (52.6)	20 (48.8)
Mismatch	10 (25.6)	0		4 (21.1)	0
Graft type			0.010			0.012
Bone marrow	4 (10.3)	16 (34.8)		1 (5.3)	15 (36.6)
Peripheral blood	35 (89.7)	30 (65.2)		18 (94.7)	26 (63.4)
Conditioning intensity			< 0.001			0.010
Myeloablative	39 (100.0)	31 (67.4)		19 (100.0)	27 (65.9)
Reduced intensity	0	15 (32.6)		0	14 (34.1)
ATG in conditioning regimen	39 (100.0)	21 (45.7)		19 (100.0)	20 (48.8)
Time from diagnosis to transplant, month	12.1 (2.5–161.1)	9.5 (2.3–53)	0.884	7.9 (1.8–28.8)	5.9 (1.5–42.9)	0.499

MDS-t= therapy related MDS, MRD=matched related donor, MUD= matched unrelated donor, MMD= mismatched donor, BM= bone marrow, PB= peripheral blood, MAC= myeloablative, RIC= reduced intensity